575 related articles for article (PubMed ID: 16374840)
1. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
4. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
6. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
Koga H; Harada M; Ohtsubo M; Shishido S; Kumemura H; Hanada S; Taniguchi E; Yamashita K; Kumashiro R; Ueno T; Sata M
Hepatology; 2003 May; 37(5):1086-96. PubMed ID: 12717389
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
9. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T
Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302
[TBL] [Abstract][Full Text] [Related]
10. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
11. Phorbol ester potentiates the growth inhibitory effects of troglitazone via up-regulation of PPARgamma in A549 cells.
Kim HJ; Woo IS; Kang ES; Eun SY; Kim GH; Ham SA; Kim HJ; Lee JH; Chang KC; Kim JH; Lee HT; Seo HG
Biochem Biophys Res Commun; 2006 Oct; 349(2):660-7. PubMed ID: 16945329
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
14. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
15. Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2.
Qiao L; Dai Y; Gu Q; Chan KW; Ma J; Lan HY; Zou B; Rocken C; Ebert MP; Wong BC
Cancer Lett; 2008 Sep; 268(2):260-71. PubMed ID: 18477501
[TBL] [Abstract][Full Text] [Related]
16. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
[TBL] [Abstract][Full Text] [Related]
17. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
Li M; Lee TW; Yim AP; Mok TS; Chen GG
J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
[TBL] [Abstract][Full Text] [Related]
19. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells.
Yoshida K; Tanabe K; Fujii D; Oue N; Yasui W; Toge T
Anticancer Res; 2003; 23(1A):267-73. PubMed ID: 12680223
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
